Drug Profile
Research programme: antibacterials - Antabio
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Antabio
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for research development in Gram-negative-infections in France
- 13 Nov 2013 Early research in Gram-negative infections in France (unspecified route)